全文获取类型
收费全文 | 1524篇 |
免费 | 132篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 36篇 |
妇产科学 | 42篇 |
基础医学 | 241篇 |
口腔科学 | 17篇 |
临床医学 | 202篇 |
内科学 | 347篇 |
皮肤病学 | 22篇 |
神经病学 | 187篇 |
特种医学 | 15篇 |
外科学 | 113篇 |
综合类 | 17篇 |
一般理论 | 6篇 |
预防医学 | 188篇 |
眼科学 | 20篇 |
药学 | 81篇 |
中国医学 | 1篇 |
肿瘤学 | 127篇 |
出版年
2024年 | 4篇 |
2023年 | 37篇 |
2022年 | 33篇 |
2021年 | 88篇 |
2020年 | 53篇 |
2019年 | 77篇 |
2018年 | 62篇 |
2017年 | 38篇 |
2016年 | 49篇 |
2015年 | 52篇 |
2014年 | 87篇 |
2013年 | 84篇 |
2012年 | 136篇 |
2011年 | 111篇 |
2010年 | 65篇 |
2009年 | 58篇 |
2008年 | 84篇 |
2007年 | 86篇 |
2006年 | 76篇 |
2005年 | 80篇 |
2004年 | 69篇 |
2003年 | 51篇 |
2002年 | 61篇 |
2001年 | 12篇 |
2000年 | 3篇 |
1999年 | 14篇 |
1998年 | 24篇 |
1997年 | 12篇 |
1996年 | 9篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 3篇 |
1989年 | 2篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1975年 | 1篇 |
1971年 | 1篇 |
1968年 | 1篇 |
1965年 | 1篇 |
1961年 | 1篇 |
1958年 | 1篇 |
排序方式: 共有1664条查询结果,搜索用时 31 毫秒
21.
Andrew G. King Georgina M. Cooke Rebecca N. Johnson Richard E. Major 《Conservation Genetics Resources》2012,4(4):893-896
Using 454 pyrosequencing and multiplex genotyping we developed 18 novel microsatellite loci in Epthianura albifrons (Jardine & Selby, 1828), a small passerine threatened by loss of coastal saltmarsh. We also tested the utility of 21 previously-developed microsatellite loci from two con-familial species, however these were weakly polymorphic in E. albifrons. The 18 loci developed for E. albifrons were polymorphic with a mean of 17.1 (±2.6SE) alleles per locus. The 18 new microsatellites will be useful tools for measuring gene flow in the Endangered population of E. albifrons. 相似文献
22.
Cristina Lalmolda Hector Prados Georgina Mateu Mariona Noray Xavier Pomares Manel Luján 《Archivos de bronconeumologia》2019,55(5):246-251
IntroductionThe aim of this study was to assess several air-pressure settings for MI–E to determine their effect on peak cough flow (PCF), and to compare the best pressures with those are more common used in the literature (±40 cmH2O) in patients with neuromuscular disorders (NMD).MethodsAdults with NMD in whom MI–E was indicated were recruited. Assisted PCF was measured by an external pneumotachograph. The protocol included 9 PCF measures per patient: 1 baseline (non-assisted), 4 with increasing inspiratory pressures without negative pressure (10, 20, 30 and 40 cmH2O or maximum tolerated), and then 4 adding expiratory pressures (?10, ?20, ?30 and ?40 cmH2O or maximum tolerated) with maximum inspiratory pressure previously achieved.ResultsTwenty one patients were included, 61% with amyotrophic lateral sclerosis (ALS). Mean PCFs with recommended pressures (±40 cmH2O) were lower than the scored in the individualized steps of the titration protocol (197.7 ± 67 l/min vs 214.2 ± 60 l/min, p < 0.05). Regarding subgroups, mean PCFmax values in ALS patients with bulbar symptoms were significantly higher than those achieved with recommended pressures (163.6 ± 80 vs 189 ± 66 l/min, p < 0.05).ConclusionThe PCFmax obtained with the protocol did not always match the recommended settings. It may be advisable to perform MI–E titration assessed by non-invasive PCF monitoring in patients with NMD, especially in ALS with bulbar involvement to improve the therapy detecting airway collapse induced by high pressures. 相似文献
23.
24.
25.
26.
Georgina Cox Thomas A. Edwards Alex J. O'Neill 《Antimicrobial agents and chemotherapy》2013,57(10):4640-4644
FusB-type proteins represent the predominant mechanism of resistance to fusidic acid in staphylococci and act by binding to and modulating the function of the drug target (elongation factor G [EF-G]). To gain further insight into this antibiotic resistance mechanism, we sought to identify residues important for the interaction of FusB with EF-G and thereby delineate the binding interface within the FusB–EF-G complex. Replacement with alanine of any one of four conserved residues within the C-terminal domain of FusB (F156, K184, Y187, and F208) abrogated the ability of the protein to confer resistance to fusidic acid; the purified mutant proteins also lost the ability to bind S. aureus EF-G in vitro. E. coli EF-G, which is not ordinarily able to bind FusB-type proteins, was rendered competent for binding to FusB following deletion of a 3-residue tract (529SNP531) from domain IV of the protein. This study has identified key regions of both FusB and EF-G that are important for the interaction between the proteins, findings which corroborate our previous in silico prediction for the architecture of the complex formed between the resistance protein and the drug target (G. Cox, G. S. Thompson, H. T. Jenkins, F. Peske, A. Savelsbergh, M. V. Rodnina, W. Wintermeyer, S. W. Homans, T. A. Edwards, and A. J. O''Neill, Proc. Natl. Acad. Sci. U. S. A. 109:2102-2107, 2012). 相似文献
27.
BS Marino PH Lipkin JW Newburger G Peacock M Gerdes JW Gaynor KA Mussatto K Uzark CS Goldberg WH Johnson J Li SE Smith DC Bellinger WT Mahle;on behalf of the American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young Council on Cardiovascular Nursing Stroke Council 《Circulation》2012,126(9):1143-1172
BACKGROUND: The goal of this statement was to review the available literature on surveillance, screening, evaluation, and management strategies and put forward a scientific statement that would comprehensively review the literature and create recommendations to optimize neurodevelopmental outcome in the pediatric congenital heart disease (CHD) population. METHODS AND RESULTS: A writing group appointed by the American Heart Association and American Academy of Pediatrics reviewed the available literature addressing developmental disorder and disability and developmental delay in the CHD population, with specific attention given to surveillance, screening, evaluation, and management strategies. MEDLINE and Google Scholar database searches from 1966 to 2011 were performed for English-language articles cross-referencing CHD with pertinent search terms. The reference lists of identified articles were also searched. The American College of Cardiology/American Heart Association classification of recommendations and levels of evidence for practice guidelines were used. A management algorithm was devised that stratified children with CHD on the basis of established risk factors. For those deemed to be at high risk for developmental disorder or disabilities or for developmental delay, formal, periodic developmental and medical evaluations are recommended. A CHD algorithm for surveillance, screening, evaluation, reevaluation, and management of developmental disorder or disability has been constructed to serve as a supplement to the 2006 American Academy of Pediatrics statement on developmental surveillance and screening. The proposed algorithm is designed to be carried out within the context of the medical home. This scientific statement is meant for medical providers within the medical home who care for patients with CHD. CONCLUSIONS: Children with CHD are at increased risk of developmental disorder or disabilities or developmental delay. Periodic developmental surveillance, screening, evaluation, and reevaluation throughout childhood may enhance identification of significant deficits, allowing for appropriate therapies and education to enhance later academic, behavioral, psychosocial, and adaptive functioning. 相似文献
28.
29.
Bertha M. Córdova-Sánchez Juan M. Mejía-Vilet Luis E. Morales-Buenrostro Georgina Loyola-Rodríguez Norma O. Uribe-Uribe Ricardo Correa-Rotter 《Clinical rheumatology》2016,35(7):1805-1816
Several classification schemes have been developed for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), with actual debate focusing on their clinical and prognostic performance. Sixty-two patients with renal biopsy-proven AAV from a single center in Mexico City diagnosed between 2004 and 2013 were analyzed and classified under clinical (granulomatosis with polyangiitis [GPA], microscopic polyangiitis [MPA], renal limited vasculitis [RLV]), serological (proteinase 3 anti-neutrophil cytoplasmic antibodies [PR3-ANCA], myeloperoxidase anti-neutrophil cytoplasmic antibodies [MPO-ANCA], ANCA negative), and histopathological (focal, crescenteric, mixed-type, sclerosing) categories. Clinical presentation parameters were compared at baseline between classification groups, and the predictive value of different classification categories for disease and renal remission, relapse, renal, and patient survival was analyzed. Serological classification predicted relapse rate (PR3-ANCA hazard ratio for relapse 2.93, 1.20–7.17, p?=?0.019). There were no differences in disease or renal remission, renal, or patient survival between clinical and serological categories. Histopathological classification predicted response to therapy, with a poorer renal remission rate for sclerosing group and those with less than 25 % normal glomeruli; in addition, it adequately delimited 24-month glomerular filtration rate (eGFR) evolution, but it did not predict renal nor patient survival. On multivariate models, renal replacement therapy (RRT) requirement (HR 8.07, CI 1.75–37.4, p?=?0.008) and proteinuria (HR 1.49, CI 1.03–2.14, p?=?0.034) at presentation predicted renal survival, while age (HR 1.10, CI 1.01–1.21, p?=?0.041) and infective events during the induction phase (HR 4.72, 1.01–22.1, p?=?0.049) negatively influenced patient survival. At present, ANCA-based serological classification may predict AAV relapses, but neither clinical nor serological categories predict renal or patient survival. Age, renal function and proteinuria at presentation, histopathology, and infectious complications constitute the main outcome predictors and should be considered for individualized management. 相似文献
30.
Villarreal-Ríos E Mathew-Quiroz A Garza-Elizondo ME Núñez-Rocha G Salinas-Martínez AM Gallegos-Handal M 《Salud pública de México》2002,44(1):7-13
OBJECTIVE: To assess the medical care costs of hypertension and their impact on the health care expenditures and on Mexico's Gross National Product (GNP). MATERIAL AND METHODS: An ecological study was conducted from June to November 1999, at Instituto Mexicano del Seguro Social (Mexican Institute of Social Security, IMSS), in Monterrey, Nuevo Leon, Mexico. A random sample of medical charts of patients with hypertension was selected, to extract data on utilization of health services and unitary costs per care episode. The cost per care episode and per hypertensive patient was calculated by adjusting the unitary cost as a function of standard and extreme utilization of IMSS health services. The resulting figure was then projected to the total population of hypertensive patients and compared to the annual health care expenditures of Mexico. RESULTS: The annual cost per patient with hypertension was $1,067 in the standard scenario and $3,913 in the extreme scenario. The annual expenditures from hypertension corresponded to 13.95% of the budget allocated to health care and to 0.71%, of Mexico's GNP. These figures changed to 51.17% and 2.61% in the extreme scenario, respectively. CONCLUSIONS: The costs of hypertension medical care account for a good portion of healthcare resources. This problem should be analyzed by multidisciplinary health teams in search of more efficient medical care alternatives. 相似文献